Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelacarsen - Novartis

Next Previous
X
Search
Drug Profile

Pelacarsen - Novartis

Alternative Names: AKCEA-APO(a)-LRx; IONIS-681257; IONIS-APO(a)-LRx; IONIS-APO-LRx; ISIS-681257; ISIS-APO(a)-LRx; ISIS-APOALRx; Pelacarsen sodium; TQJ 230

Latest Information Update: 22 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Novartis
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action Apolipoproteins A expression inhibitors; Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipoproteinaemia

Most Recent Events

  • 24 Apr 2024 Novartis Pharmaceuticals initiates a phase III trial for Hyperlipoproteinaemia in USA (SC) in May 2024 (NCT06267560)
  • 07 Mar 2024 Novartis initiates a phase II trial in Hyperlipoproteinaemia in United Kingdom, Israel, USA, Canada, Czech Republic, Switzerland (SC) (NCT05646381)
  • 20 Feb 2024 Novartis Pharmaceuticals plans a phase III trial in Hyperlipoproteinaemia in USA (SC) in May 2024 (NCT06267560)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top